Riociguat, a stimulator of soluble guanylate cyclase, has been globally approved for the treatment of PAH and inoperable CTEPH and persistent/recurrent PH after pulmonary endarterectomy. Findings from the phase III CHEST and PATENT studies indicate that riociguat significantly improves exercise capacity and a range of secondary end points, including pulmonary hemodynamics, NT-proBNP levels, and WHO FC, in patients with inoperable CTEPH and persistent/recurrent CTEPH and in PAH.